Which has stronger valuation and earnings, INMD or OBIO?

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.38 $93.83M $1.23 12.45 Orchestra BioMed $32.72M 7.76 -$52.70M -$0.97 N/A

Is INMD or OBIO more profitable?

InMode has a net margin of 20.69% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 11.99% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% Orchestra BioMed -166.96% -157.46% -60.18%

Does the media prefer INMD or OBIO?

In the previous week, Orchestra BioMed had 1 more articles in the media than InMode. MarketBeat recorded 5 mentions for Orchestra BioMed and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat Orchestra BioMed's score of 0.40 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, OBIO or SIBN?

SiBone has higher revenue and earnings than Orchestra BioMed. SiBone is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $32.72M 7.76 -$52.70M -$0.97 N/A SiBone $213.60M 3.86 -$18.90M -$0.34 N/A

Is OBIO or SIBN more profitable?

SiBone has a net margin of -6.85% compared to Orchestra BioMed's net margin of -166.96%. SiBone's return on equity of -8.23% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% SiBone -6.85% -8.23% -6.07%

Does the media prefer OBIO or SIBN?

In the previous week, SiBone had 10 more articles in the media than Orchestra BioMed. MarketBeat recorded 15 mentions for SiBone and 5 mentions for Orchestra BioMed. SiBone's average media sentiment score of 0.49 beat Orchestra BioMed's score of 0.40 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor OBIO or AVR?

In the previous week, Anteris Technologies Global had 13 more articles in the media than Orchestra BioMed. MarketBeat recorded 18 mentions for Anteris Technologies Global and 5 mentions for Orchestra BioMed. Anteris Technologies Global's average media sentiment score of 0.49 beat Orchestra BioMed's score of 0.40 indicating that Anteris Technologies Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anteris Technologies Global 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CBLL or OBIO?

In the previous week, CeriBell had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 6 mentions for CeriBell and 5 mentions for Orchestra BioMed. CeriBell's average media sentiment score of 0.68 beat Orchestra BioMed's score of 0.40 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Orchestra BioMed (OBIO) Competitors

$4.24 +0.09 (+2.17%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$4.18 -0.06 (-1.39%)

As of 08/7/2026 07:56 PM Eastern

Compare

OBIO vs. INMD, SIBN, AVR, SSII, and CBLL

Should you buy Orchestra BioMed stock or one of its competitors? MarketBeat compares Orchestra BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orchestra BioMed include InMode (INMD), SiBone (SIBN), Anteris Technologies Global (AVR), SS Innovations International (SSII), and CeriBell (CBLL). These companies are all part of the "healthcare equipment" industry.

How does Orchestra BioMed compare to InMode?

InMode (NASDAQ:INMD) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

InMode has a net margin of 20.69% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 11.99% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.38	$93.83M	$1.23	12.45
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A

68.0% of InMode shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Orchestra BioMed had 1 more articles in the media than InMode. MarketBeat recorded 5 mentions for Orchestra BioMed and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat Orchestra BioMed's score of 0.40 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InMode has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

InMode presently has a consensus target price of $16.00, suggesting a potential upside of 4.51%. Orchestra BioMed has a consensus target price of $13.60, suggesting a potential upside of 220.75%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

InMode beats Orchestra BioMed on 10 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to SiBone?

Orchestra BioMed (NASDAQ:OBIO) and SiBone (NASDAQ:SIBN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, SiBone had 10 more articles in the media than Orchestra BioMed. MarketBeat recorded 15 mentions for SiBone and 5 mentions for Orchestra BioMed. SiBone's average media sentiment score of 0.49 beat Orchestra BioMed's score of 0.40 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Orchestra BioMed currently has a consensus price target of $13.60, suggesting a potential upside of 220.75%. SiBone has a consensus price target of $24.29, suggesting a potential upside of 30.50%. Given Orchestra BioMed's higher possible upside, research analysts plainly believe Orchestra BioMed is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
SiBone	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

SiBone has higher revenue and earnings than Orchestra BioMed. SiBone is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A
SiBone	$213.60M	3.86	-$18.90M	-$0.34	N/A

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 4.0% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Orchestra BioMed has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, SiBone has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

SiBone has a net margin of -6.85% compared to Orchestra BioMed's net margin of -166.96%. SiBone's return on equity of -8.23% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
SiBone	-6.85%	-8.23%	-6.07%

Summary

SiBone beats Orchestra BioMed on 12 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Anteris Technologies Global?

Orchestra BioMed (NASDAQ:OBIO) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Orchestra BioMed presently has a consensus price target of $13.60, indicating a potential upside of 220.75%. Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 79.57%. Given Orchestra BioMed's higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Anteris Technologies Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Orchestra BioMed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

Orchestra BioMed has a net margin of -166.96% compared to Anteris Technologies Global's net margin of -5,148.78%. Anteris Technologies Global's return on equity of -124.76% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

Orchestra BioMed has higher revenue and earnings than Anteris Technologies Global. Orchestra BioMed is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A
Anteris Technologies Global	$1.91M	454.08	-$94.14M	-$2.23	N/A

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Anteris Technologies Global had 13 more articles in the media than Orchestra BioMed. MarketBeat recorded 18 mentions for Anteris Technologies Global and 5 mentions for Orchestra BioMed. Anteris Technologies Global's average media sentiment score of 0.49 beat Orchestra BioMed's score of 0.40 indicating that Anteris Technologies Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anteris Technologies Global	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Orchestra BioMed beats Anteris Technologies Global on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Orchestra BioMed had 5 more articles in the media than SS Innovations International. MarketBeat recorded 5 mentions for Orchestra BioMed and 0 mentions for SS Innovations International. Orchestra BioMed's average media sentiment score of 0.40 beat SS Innovations International's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Overall Sentiment
SS Innovations International	Neutral
Orchestra BioMed	Neutral

SS Innovations International has a beta of -1.92, indicating that its stock price is 292% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

SS Innovations International currently has a consensus target price of $7.00, indicating a potential upside of 85.68%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 220.75%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

SS Innovations International has higher revenue and earnings than Orchestra BioMed. SS Innovations International is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$48.47M	15.57	-$12.13M	-$0.05	N/A
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A

SS Innovations International has a net margin of -20.69% compared to Orchestra BioMed's net margin of -166.96%. SS Innovations International's return on equity of -23.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Orchestra BioMed beats SS Innovations International on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

53.2% of Orchestra BioMed shares are owned by institutional investors. 17.7% of CeriBell shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CeriBell currently has a consensus price target of $22.20, indicating a potential upside of 18.02%. Orchestra BioMed has a consensus price target of $13.60, indicating a potential upside of 220.75%. Given Orchestra BioMed's higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Orchestra BioMed has lower revenue, but higher earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	8.01	-$53.41M	-$1.63	N/A
Orchestra BioMed	$32.72M	7.76	-$52.70M	-$0.97	N/A

In the previous week, CeriBell had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 6 mentions for CeriBell and 5 mentions for Orchestra BioMed. CeriBell's average media sentiment score of 0.68 beat Orchestra BioMed's score of 0.40 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell has a net margin of -63.51% compared to Orchestra BioMed's net margin of -166.96%. CeriBell's return on equity of -38.19% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

CeriBell has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Summary

CeriBell beats Orchestra BioMed on 11 of the 17 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$253.90M	$5.82B	$7.02B	$13.00B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-4.37	24.26	271.11	25.19
Price / Sales	7.76	62.05	590.37	78.11
Price / Cash	N/A	33.10	71.81	50.72
Price / Book	4.46	5.70	13.25	6.22
Net Income	-$52.70M	$148.58M	$3.45B	$342.66M
7 Day Performance	6.53%	4.75%	4.67%	4.41%
1 Month Performance	8.16%	0.71%	-1.28%	-1.10%
1 Year Performance	56.46%	4.93%	77.33%	23.99%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	3.87 of 5 stars	$4.24 +2.2%	$13.60 +220.8%	+56.5%	$253.90M	$32.72M	N/A	4	Upcoming Earnings
INMD InMode	1.346 of 5 stars	$15.22 -1.0%	$16.00 +5.1%	+8.5%	$874.85M	$370.49M	11.19	480	Positive News Earnings Report Analyst Forecast
SIBN SiBone	3.3623 of 5 stars	$18.16 -1.5%	$24.29 +33.7%	+18.7%	$805.40M	$200.93M	N/A	350	News Coverage Earnings Report Analyst Forecast Insider Trade
AVR Anteris Technologies Global	2.2977 of 5 stars	$8.26 -0.2%	$16.00 +93.7%	+146.1%	$804.03M	$1.91M	N/A	138	News Coverage Upcoming Earnings Insider Trade
SSII SS Innovations International	1.3504 of 5 stars	$3.94 +2.9%	$7.00 +77.7%	-44.3%	$788.51M	$42.49M	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. INMD, SIBN, AVR, SSII, and CBLL

How does Orchestra BioMed compare to InMode?

Summary

How does Orchestra BioMed compare to SiBone?

Summary

How does Orchestra BioMed compare to Anteris Technologies Global?

Summary

How does Orchestra BioMed compare to SS Innovations International?

Summary

How does Orchestra BioMed compare to CeriBell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. INMD, SIBN, AVR, SSII, and CBLL

How does Orchestra BioMed compare to InMode?

Is INMD or OBIO more profitable?

Which has stronger valuation and earnings, INMD or OBIO?

Do insiders & institutionals hold more shares of INMD or OBIO?

Does the media prefer INMD or OBIO?

Which has more volatility and risk, INMD or OBIO?

Do analysts prefer INMD or OBIO?

Summary

How does Orchestra BioMed compare to SiBone?

Does the media prefer OBIO or SIBN?

Do analysts prefer OBIO or SIBN?

Which has better valuation & earnings, OBIO or SIBN?

Do institutionals and insiders hold more shares of OBIO or SIBN?

Which has more risk & volatility, OBIO or SIBN?

Is OBIO or SIBN more profitable?

Summary

How does Orchestra BioMed compare to Anteris Technologies Global?

Do analysts rate OBIO or AVR?

Which has more volatility and risk, OBIO or AVR?

Is OBIO or AVR more profitable?

Which has stronger earnings and valuation, OBIO or AVR?

Do institutionals and insiders have more ownership in OBIO or AVR?

Does the media favor OBIO or AVR?

Summary

How does Orchestra BioMed compare to SS Innovations International?

Does the media refer more to SSII or OBIO?

Which has more volatility and risk, SSII or OBIO?

Do analysts recommend SSII or OBIO?

Which has stronger valuation & earnings, SSII or OBIO?

Is SSII or OBIO more profitable?

Do institutionals and insiders have more ownership in SSII or OBIO?

Summary

How does Orchestra BioMed compare to CeriBell?

Do institutionals & insiders have more ownership in CBLL or OBIO?

Do analysts recommend CBLL or OBIO?

Which has better earnings and valuation, CBLL or OBIO?

Does the media refer more to CBLL or OBIO?

Is CBLL or OBIO more profitable?

Which has more risk & volatility, CBLL or OBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools